Transfusion is generally very safe. However, in a small number of cases, it leads to mild and even serious -life-threatening -hazards (most often after platelet component transfusion). In cases where no preventable accident happens (that exclude infection, chain error, malpractice, antigen-antibody conflict), the symptomatology resembles inflammation. The present essay reports on the causes of inflammation in transfusion and in which way one may intervene on the different steps of the processfrom donor to patient -to limit such incidents/accidents.
While the use of transfusions in emergency may be on the decline, indications for medical purposes are forefront. Transfusion has become a treatment program per se, in transplantation and in hematological cell diseases; however, practice is changing, as targets are constantly revisited based on large-scale trials. A major achievement has been the reduction of transfusion-transmitted infections. Another one is the serious reduction of most chronic as well as acute immunological adverse events. Best practice and surveillance programs have been implemented in an attempt to decrease non-tolerance hazards; human error is now principally responsible for residual risks that comprise e.g. of chain errors ("Wrong product to the wrong patient") (l).
In general, transfusions are extremely safe. NearlyhalfoftheAdverse Events (AEs) observed are linked with Platelet Component (PC) transfusions, while PC transfusions make up approximately 10% of labile blood components (LBCs) transfused (in France); the other half of AEs are encountered with red blood cell concentrates (RBCCs; approximately 80% of LBCs transfused); these records are sound in France because of the systematic record of AEs of all degrees of severity -it is less informative in countries with no systematic report of minor AEs such as in the UK. Systematic leukoreduction has largely contributed to the reduction of the former frequent AEs [leukoreduction is applied so far in all developed countries, unlike developing countriesthough with different residual cell targets, that are <10 6 in Europe upon the recommendations of the EDQM (2)]; however, in North-America and Europe, for example, some AEs remain that are inflammatory in nature; in those cases, they frequently present with acute symptomatology and are termed acute transfusion reactions (ATRs). If one compares RBCCs and PCs, leukoreduction reaches the same target; but it is possible that residual leukocytes exert more noxious inflammatory reactions within young LBCs such as PCs, than in older LBCs such as RBCCs. Therapeutic plasma (the remaining 10% of LBCs transfused) is quite negligible in terms of AEs but can eventually cause such ATRs. Inflammatory type ATRs come in two natures: they are, or are not, associated with antigen/antibody (Ag/ Ab) conflicts. Among the former, are life threatening acute allergy-and transfusion-related acute lung injury (TRALI) (of note, whereas all TRALI cases are acutely inflammatory, Abs may be absent or no longer detectable, making this pathology particularly vicious).
It has long been acknowledged that factors other than leukocytes are linked to inflammatory-type symptoms (3). These data have been extended in more recent observations (4) . One indirect argument is that pathogen inactivation processes, in the rare blood establishments (BEs) which happen to implement it, prevent the release of many of the leukocyte-released cytokines, but do not seem to significantly alter the occurrences of AEs. A more direct argument is that a large array of inflammatory products are released or secreted by platelets while stored to constitute the PC inventory (5) . Furthermore, cytokine and chemokine (and the like) products, collectively termed "biological response modifiers" (BRMs), are secreted, with a peak reached generally by day 3 or 4 (6) .
A characteristic issue ofPCs is that platelets suffer activation during their shelf-life; however, there is no deliberate stimulus. The collection, processing, and storage (gentle rotation, exposure to plastics and gases) are apparently sufficient to deliver activation stimuli through various processes that can activate platelets (7) . Nevertheless, it is possible that residues or moieties from infectious agents, particularly bacteria (even ifthe bacteria are not alive), constitute some stimuli that elicit platelets to secrete copious amounts of BRMs.
One such factor, soluble CD40-ligand (sCD40L), has been consistently identified as a major cytokinelike product secreted from platelets, during both homeostasis and in pathology; it is thought that 95% of sCD40L found in plasma originates from platelets (8) . This factor is central to normal immune responses; it is also involved in pathology (9) . The contributions ofplatelets and their secretory products have been identified in tissue pathology (10, 11) . sCD40L has also been identified as being chiefly responsible for ATRs (12, 13) , but its role in TRALI has recently been disputed (14) .
Numerous BRMs other than sCD40L are associated with platelet-linked inflammation; some were expected but others were a surprise because they had not previously been described as having an association with platelets. Among those BRMs, some are present in normal platelet physiology but others are found only in platelets that have led to an ATR (13, 15, 16) . The key is to establish a direct link between clinical observations and ex vivo or experimental data. A recent survey of ours attempted to examine this link, and to further establish predictive outcomes of acute transfusion reactions based on the presence/absence of certain BRMs in PCs to be delivered (16) . Only large-scale clinical surveys would indicate who is at risk of donating or of receiving a possible pro-inflammatory platelet component. Even so, it is possible that different factors (such as treatment type, or an individual patient's condition, for example) may either reduce or increase the risk of developing inflammation contrary to a prediction based on a model.
Platelet-linked BRMs are not the sole factors responsible for AEs and ATRs since, while ageing, they emit numerous microparticles which are loaded with pro-inflammatory and pro-thrombotic factors (17) , and altered membrane lipid moieties that are also inflammatory and noxious (18) .
One of our prevalent hypotheses regarding transfusion-linked inflammation is aligned with what is currently known about TRALI (19) , or Transfusion-linked allergy (20) ; that it is a twohit (TRALI) or a two-prong (Allergy) process. We hypothesize that the first hit is the presence ofnoxious BRMs or microparticles issued from the LBC and infused in the recipient. This first hit sensitizes the recipient to developing inflammation. The second hit is the existence of favorable conditions in the recipient that may be either linked to his/her present condition (and causal disease) or to his/her genetic background (hyper-reactivity to pro-inflammatory factors because of, for example, elevated expression of receptors for the incriminated BRM). If this theory is correct, it would mean that some donors' stored platelets, for example, are prone to secrete certain BRMs that can be deleterious in recipients. It would also mean that some recipients are prone to developing inflammatory symptoms. A direct link between the two branches of this hypothesis remains to be ascertained by large-scale clinical surveys.
Platelets therefore appear to: a) be reactive to a large number of danger signals because they display 
(donated cells express genetically encoded motifs that decorate the cells and that may. or may not, conflict with recipient s circulating or tissue residing effectors; the donor may also have taken, by ingestion or by injection, conflicting moieties such as selfprescribed drugs or alimentary complements etc.; ii) the labile blood component processed from his/her donation (that may sufferfrom collection, preparation/processing, storage, and emit molecular signs ofstress, that can, or not, be sensed by danger signal sensors expressed on innate immune cells in the recipient) ; iii) the recipient (who may show genetically encoded receptors for moieties brought into his/her circulation by the labile blood component, whose origin isfrom the donor or the process).
an array of pathogen recognition receptors, such as toll-like receptors (21) , but also receptors for the Fe region of Igs, and complement receptors; b) respond differentially to distinct types ofdanger (e.g. infection, but probably others also, such as those that can be inflicted by the collection/production/storage of a PC); c) activate an almost complete signalosome and their secretome (22) ; and d) secrete a large variety of BRMs. These conditions aid understanding of the issue of PCs being at risk of eliciting occasional ATRs.
Post-transfusion inflammation is not restricted to platelets; however, RBCC involvement is a little more difficult. Inflammatory-type AEslATRs occur occasionally after RBCC transfusion (23) . It is possible that residues of leukocytes and/or RBC membrane bound cytokines/chemokines playa role. However, this is unlikely if they are in some way related to BRMs that are in trace amounts when infused into the recipient. A possible cause is the presence of micropartic1es, especially in ageing RBCCs (24) . However, despite many attempts and multiple surveys specifically examining younger vs older blood components, as data are conflicting, no firm conclusion can be drawn as yet. Another cause may be that the collection/processing/storage conditions may create "dangers" that are sensed by scavenger cells or that directly insult the recipient's cells in the circulatory system or vasculature. We recently obtained evidence showing that the mode of preparation of RBCCs was important in creating scavenger signals in experimental conditions (25) .
Prevention programs have been established in an attempt to reduce for example TRALI, based on deferral of plasma and platelet donations from HLA antibody positive donor candidates, which has proved to be highly effective in many transfusion systems. Programs aimed at reducing acute allergy have been less effective, but the physiopathology of this hazard remains a largely unexplained peculiarity in the transfusion field. Complementary safety measures would be beneficial to patients, however, they may be extremely difficult to establish and cost-effectiveness is debatable, especially under the current paradigm of transfusion that is based on gross immune-hematology matching. Another paradigm would be based on two independent sets of genetically controlled factors i.e., from the donors and from the recipients, thus novel safety measures could be considered or even conceived.
Indeed, transfusion-linked inflammation may be the result of a combination of factors associated with the donor, the blood component, and the recipient (as shown in Fig. I) . The only factor that can currently be targeted is the LBC.
The identification of parameters that may be related to patients (recipients) would be desirable to identify "at risk patients" and for the application of measures to prevent the severity of hazards. If parameters are linked to donors, the situation becomes more difficult because further medical investigation of donors will likely threaten the blood component inventory. It also poses the question of how to explain to a blood donor that he/she is perfectly safe and healthy, but "at risk" of inflicting harm in certain recipients -a medically, ethically and psychologically difficult question to address. Alternatively, transfusion medicine may become one of the medical specialties where personalized medicine is used: providing a given patient with the blood component that best fits his/her condition.
